* Affymetrix Inc., of Santa Clara, Calif., entered an agreement with Roche Bioscience, of Palo Alto, Calif., for use of the former's GeneChip technology in analyzing gene expression. Financial terms were not disclosed. Roche Bioscience is a unit of Basel, Switzerland-based Roche Holding Ltd.

* Boston Life Sciences Inc., of Boston, filed an investigational new drug application with the FDA to begin clinical trials of Altropane, a radio-imaging agent for diagnosis of Parkinson's disease. The company expects to complete Phase I/II and Phase III studies of Altropane this year in preparation for filing for market approval by the end of 1997.

* Celgene Corp., of Warren, N.J., submitted an investigational new drug application to begin Phase I/II clinical trials of a "chirally pure version of methylphenidate hydrochloride for treatment of attention deficit hyperactivity disorder in children. The drug is a single isomer version of methylphenidate, which is sold by Novartis, of Basel, Switzerland, under the brand name Ritalin.

* Cortex Pharmaceuticals Inc., of Irvine, Calif., said it raised $1.5 million through the sale of preferred stock. The funds represented proceeds from the second of three tranches in a private placement aimed at generating a total of $4 million.

* Diatide Inc., of Londonderry, N.H., began Phase III trials of its P829 techtide imaging agent in detection of non-small cell lung cancer. The diagnostic is a combination of a synthetic peptide and radioactive technetium-99m.

* Gene Logic Inc., of Columbia, Md., entered an agreement with Bayor College of Medicine in Houston to identify genes associated with prostate cancer. Gene Logic will use its technology to compare gene expression and regulation in cancerous and normal prostate tissue samples provided by Baylor.

* Genelabs Technologies Inc., of Redwood City, Calif., completed its first Phase III trial of the company's lead compound, GL701, for lupus. The drug is a form of dehydroepiandrosterone, a hormone found in abnormally low amounts in lupus patients. Data from the placebo-controlled study involving 192 patients will be released in the first or second quarter of 1997.

* GeneTrace Systems Inc., of Menlo Park, Calif., said it achieved two milestones in its research and development agreement with Incyte Pharma-
ceuticals Inc
., of Palo Alto, Calif. The companies did not disclose the amount of the milestone payments. GeneTrace licensed Incyte access to technology for identifying gene expression patterns.

* Gliatech Inc., of Cleveland, signed a licensing agreement with Chugai Pharmaceutical Co. Ltd., of Tokyo, for development of Gliatech's Adcon-L and Adcon-T/N products in Japan. The products are post-surgical, anti-adhesion gels. Adcon-L is used in back surgery and Adcon-T/N is used in tendon and peripheral nerve surgeries. Financial terms were not disclosed.

* IGG International Inc., of Cambridge, Mass., received approval from the FDA to begin clinical trials with the company's lead anti-cancer product, GBC-590. The drug is a carbohydrate-based compound designed to disrupt cellular recognition processes involved in cancer metastasis.

* Isis Pharmaceuticals Inc., of Carlsbad, Calif., entered a collaboration with the University of California at San Francisco under a Biotechnology Strategic Targets for Alliances in Research grant. The program is sponsored by the University of California President's Initiative for Industry-University Cooperative Research. The work will focus on identifying genes in the HIV-1 genome for use in developing drugs to treat the AIDS virus.

* VIMRx Pharmaceuticals Inc., of Wilmington, Del., began a Phase I/II trial of its antiviral drug, VIMRxyn, for chronic hepatitis C. The drug is a chemically synthesized hypericin and the studies will involve 24 patients.